Mayo Clinic Laboratories > BioPharma Diagnostics > Testing > Neurology

Neurology

FULL SPECTRUM OF NEUROLOGICAL DISEASE TESTING

A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories. Our highly specialized neurology testing menu features more than 400 neurologist-backed assays to evaluate the simplest to most complex cases. From analyses for Alzheimer’s disease and dementia to targeted antibody detection for autoimmune neurology conditions, our robust testing library provides partners with results that move solutions through the development pipeline.

With 19 subspecialty labs that perform testing, we are at the forefront of research that integrates novel biomarker discoveries into our evaluations. Our clinical experience gives us the expertise to develop tests that deliver actionable answers.

To learn more about our testing, view our biopharma-specific test catalog and full test catalog.

Test menu

Biopharma only testing Biopharma only testing
Biopharma only testing

Our BioPharma Diagnostics-specific neurology testing is designed to provide answers for your patients.

Full suite of neurology testing Full suite of neurology testing
Full suite of neurology testing

Mayo Clinic Laboratories is leading an evolution in neurology testing. Propelled by ongoing discoveries of clinically relevant biomarkers, our laboratory scientists integrate research findings into test development and implementation. Collaboration between our labs and the clinical practice at Mayo Clinic supports development of clinically validated testing that delivers actionable answers for patients.

Dementia Dementia
Dementia

Offering the industry’s most sophisticated suite of testing available, including biomarker evaluations, autoimmune panels, testing for rapidly progressive cases, and an innovative combination assay, Mayo Clinic Laboratories is a one-stop laboratory solution for dementia and Alzheimer’s disease testing.

Demyelinating disease Demyelinating disease
Demyelinating disease

Driven by ongoing research into the presence of antibody biomarkers in patients with immune-mediated demyelinating neuropathy, Mayo Clinic Laboratories has developed several unique, highly accurate assays that use pioneering methods to identify specific biomarkers associated with the harmful immune response. Order these tests when nerve conduction studies show prolonged distal latency or marked slowing of conduction velocities.

Epilepsy Epilepsy
Epilepsy

Proper identification of immune-mediated epilepsy is vital to directing appropriate treatment. Our autoimmune epilepsy evaluation detects for more than a dozen antibody biomarkers related to autoimmune causes.

Mitochondrial disease Mitochondrial disease
Mitochondrial disease

We offer four molecular test options that can complement radiological and histological evaluations to confirm a mitochondrial diagnosis and identify a specific mitochondrial syndrome. Rather than a series of targeted panels or single-gene analysis, we recommend sequencing the entire mitochondrial genome and/or performing a comprehensive nuclear gene panel.

Movement disorders Movement disorders
Movement disorders

Our comprehensive autoimmune movement disorders panel is continuously updated to include newly discovered antibody biomarkers and uses advanced testing approaches to detect actionable antibodies. Data-backed and developed by our autoimmune neurology experts, our evaluations include detection of several antibody biomarkers available only at Mayo Clinic Laboratories.

Neuromuscular disorders Neuromuscular disorders
Neuromuscular disorders

Our distinctive approach to testing for genetic neuromuscular disorders uses phenotypic information to streamline diagnosis. Phenotype-specific panels enable targeted testing, improving diagnosis and minimizing uncertain results.

Peripheral neuropathy Peripheral neuropathy
Peripheral neuropathy

Our hereditary peripheral neuropathy test menu includes both comprehensive and targeted NGS panels to assist in identifying genetic causes across the spectrum of peripheral neuropathies.

Sleep disorders Sleep disorders
Sleep disorders

Our testing to assess for narcolepsy evaluates for low concentrations of orexin-A/hypocretin-1 in cerebrospinal fluid. Sensitive and specific, this evaluation provides results that can guide appropriate treatment for patients.

Neurology testing overview

The rapid expansion of neurology testing has resulted in the discovery of increasing numbers of clinically relevant biomarkers. Mayo Clinic Laboratories collaborates closely with the clinical practice to develop and offer advanced testing — much of which is unavailable anywhere else — to address the most difficult questions.

Our laboratories are led by board-certified clinical neurologists and clinical chemists who have extensive experience using testing to guide patient care. These experts are available for consultations on test selection and results interpretation. Our physicians are committed to research and discovery to pave the way for the future of neurology testing.

Comprehensive disease testing

A collaboration with BioPharma Diagnostics includes access to the neurologic disease testing capabilities of Mayo Clinic Laboratories, including: 

  • Alzheimer's disease
  • Demyelinating disease
  • Epilepsy
  • Mitochondrial disease
  • Movement disorders
  • Neuromuscular disorders
  • Peripheral neuropathy
  • Sleep disorders
News and updates

The latest

Diagnostic ecosystem boosts access to timely Alzheimer’s disease testing

Mayo Clinic Laboratories has developed a cutting-edge suite of Alzheimer's disease testing. The newest assays use blood samples, avoiding the need for lumbar punctures to obtain cerebrospinal fluid. The testing suite exemplifies Mayo Clinic Laboratories' innovative business approach. As a platform company, Mayo Clinic is creating a diagnostics ecosystem to meet a wide range of testing needs and help physicians order the right tests for their patients.

Learn more
Myasthenia Gravis [Test in Focus]

Christopher Klein, M.D., discusses Mayo Clinic’s updated myasthenia gravis and Lambert-Eaton syndrome testing approach. Automatic reflex to second-line testing saves time and increases sensitivity and specificity to confirm diagnosis in patients with atypical presentation.

Thank you to all our staff during the time of COVID-19

Thank you to our staff at Mayo Clinic who step up daily during this time of need to provide access to testing during the global pandemic. We appreciate each one of you and all the sacrifices you personally have made throughout this past year.

Paraneoplastic Vision Loss Evaluation [Test in Focus]

Andrew McKeon, M,B., B.Ch., M.D., provides an overview of Mayo Clinic Laboratories' new paraneoplastic vision loss evaluation — a test that can help direct a cancer diagnosis and guide treatment. He reviews why this test was developed, when it should be ordered, and how the results can affect patient care.

Behind the scenes in neural antibody testing

In this month’s “Hot Topic,” John Mills, Ph.D., explains the central role of tissue immunofluorescence in the identification of neural antibodies and discusses the benefits of an integrated laboratory approach to the development and validation of novel antibody biomarkers.

Sleep Review explores orexin testing for narcolepsy with Joshua Bornhorst, Ph.D.

Dr. Bornhorst explains orexin testing's role in diagnosing type 1 narcolepsy and the significance of the test's availability through Mayo Clinic Laboratories.

Discussions with the Directors

A new episode of "Discussions with the Directors" is available on the topic of paraneoplastic testing - when is it appropriate and what is the way ahead. Listen Now!

The Role of CSF in Alzheimer’s Disease

This "Specialty Testing" webinar will discuss Cerebrospinal fluid (CSF), which has been used in research on Alzheimer's disease for decades. Only recently, have platforms been developed to standardize measurements across laboratories.

Pediatric Autoimmune CNS Disorders Evaluation

This “Specialty Testing” webinar will address the clinical presentations, evaluation (including diagnostic antibody testing), and treatment of autoimmune pediatric CNS disorders, including encephalitides and myelopathies.

Autoimmune Axonal Evaluation [Test in Focus]

Divyanshu Dubey, M.B.B.S. gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.

Pediatric CNS Disorder Evaluations [Test in Focus]

Autoimmune encephalitis and myelitis is increasingly recognized as a cause of CNS disease in children and teens. Andrew McKeon, M.B., B.Ch., M.D, gives an overview of this test available through Mayo Clinic Laboratories. He discusses when this testing should be ordered, how this testing compares to other testing approaches, and what clinical action can be taken due to the results of this testing.

Antibody Prevalence in Epilepsy and Encephalopathy (APE2) Score

In this month’s “Hot Topic,” Divyanshu Dubey, M.B.B.S., discusses how patients with encephalopathy and/or epilepsy of unknown etiology may have an autoimmune or paraneoplastic cause.

Autoimmune Myelopathy

This “Specialty Testing” webinar will describe the clinical, radiologic, and serologic characteristics of autoimmune myelopathies and their mimics.

View More
INTERESTED IN LEARNING MORE?

Fill out the form below and one of our specialists will be in touch.

Are you a patient? Click here.